



Supplementary Fig. S4. *ESRI* mutation analysis in ctDNA. (A) Prevalence of individual *ESRI* mutations in baseline ctDNA samples by the BEAMing digital PCR (dPCR) and FACT next generation sequencing (NGS) assays, graphed as the percentage of *ESRI* mutant samples with the individual mutation detected. (B) *ESRI* mutation analysis of matched ctDNA samples by the BEAMing and FACT assays by patient and time point. Baseline BEAMing sample from patient 31 was not evaluable for the *ESRI* Y537N mutation, which was detected in the end-of-treatment sample from that patient; baseline BEAMing sample from patient 40 was not evaluable for the *ESRI* E380Q mutation, which was detected in the C3D1 and C6D1 samples. MND, mutation not detected.

A. Prevalence of *ESR1* mutations at baseline



B. BEAMing and FACT analyses of ctDNA samples



Time point	<i>ESR1</i> alteration				FACT MND	BEAM MND	BEAM MUT
Baseline	D538G	L536H	L536Q	E380Q	27 (51%)	6 (11%)	
Cycle 3 Day 1	Y537S	L536P	S463P	S463P	0	20 (38%)	
Cycle 6 Day 1	Y537N	L536R	No sample	No sample			
End of treatment	Y537C	L536Q	Mutation not detected	Mutation not detected			

MND, mutation not detected; MUT, mutation